‘Smoker’s cough’ drug succeeds in late-stage trials, Novartis says. Four more trials will be completed this year, to prepare for United States Food and Drug Administration approval, as well as that of European and Japanese drug regulators.
Caused mainly by tobacco smoking, air pollution or job exposure to lung hazards, chronic obstructive pulmonary disease (COPD) — known commonly as smoker’s cough — is painful and debilitating. It forces its sufferers to cough most of the time, to take painful breaths, and to fall into debilitating bouts of breathlessness.
Chronic bronchitis and emphysema — over-inflation of the air sacs or alveoli in the lungs — are common symptoms that progress slowly and in time, lead to an irreversible loss of lung function. Around three-fourths of patients with advanced COPD are unable to perform normal everyday activities — and a good number of them go on to die when their lungs collapse.
Continue reading “Smoker’s Cough: Will Novartis’ Drug QVA149 Be Effective vs. COPD?”